 23 January 2023 Clinigen divests Proleukin to Iovance Biotherapeutics for 166.7 million The deal includes a 41.7 million milestone payment and double-digit Proleukin global sales royalties Clinigen Limited Clinigen the Company, the global pharmaceutical services company, has entered into an agreement to divest Proleukin interleukin-2 aldesleukin, to Iovance Biotherapeutics, Inc. NASDAQ: IOVA Iovance, a late-stage... The post Clinigen divests Proleukin to Iovance Biotherapeu... 